Shortness Of Breath Questionnaire Validation Study

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

NCT00731770 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

NCT01772147 ·Status: COMPLETED ·Phase: PHASE3

Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV

NCT00527826 ·Status: COMPLETED ·Phase: PHASE4

Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis

NCT02782312 ·Status: COMPLETED ·Phase: PHASE4

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

NCT00568347 ·Status: COMPLETED

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134 ·Status: COMPLETED ·Phase: PHASE3

Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01131806 ·Status: UNKNOWN ·Phase: PHASE4

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00268216 ·Status: COMPLETED ·Phase: PHASE3

Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease

NCT00549146 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

NCT01342913 ·Status: COMPLETED ·Phase: PHASE3

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

NCT02573870 ·Status: COMPLETED ·Phase: PHASE2

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

NCT00403286 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

NCT00774761 ·Status: COMPLETED ·Phase: PHASE2

A Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01245569 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

NCT01393145 ·Status: WITHDRAWN ·Phase: PHASE3

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

NCT01321463 ·Status: COMPLETED ·Phase: PHASE2

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

NCT00741767 ·Status: WITHDRAWN ·Phase: NA

Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment

NCT01395875 ·Status: COMPLETED

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

NCT00517634 ·Status: COMPLETED ·Phase: PHASE4

A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50

NCT03562923 ·Status: UNKNOWN ·Phase: PHASE3

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

NCT00115492 ·Status: COMPLETED ·Phase: PHASE4

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01381471 ·Status: COMPLETED

The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD

NCT01243788 ·Status: UNKNOWN ·Phase: PHASE4

Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD

NCT01213693 ·Status: COMPLETED ·Phase: NA

Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01636076 ·Status: COMPLETED ·Phase: PHASE2